Disassembly of the Shieldin Complex by TRIP13

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• DNA double-strand breaks (DSBs) are repaired by homologous recombination (HR) and classical non-homologous end joining (C-NHEJ).
• The choice between HR and C-NHEJ is regulated by DNA end-resection, which is impeded by the 53BP1-REV7-Shieldin complex.
• Dysregulation of this pathway confers PARP inhibitor resistance in BRCA1-deficient cancers, highlighting its clinical significance.

Purpose of the Study:

• To investigate the role of the ATPase TRIP13 in regulating DSB repair pathways.
• To elucidate the mechanism by which TRIP13 influences the REV7-Shieldin complex and DNA end-resection.
• To connect these findings with existing knowledge on DSB repair and HORMA proteins, proposing testable hypotheses.

Main Methods:

• Review and integration of existing research on DSB repair pathways, including HR and C-NHEJ.
• Analysis of the regulatory network involving 53BP1, REV7, Shieldin, and TRIP13.
• Formulation of hypotheses regarding TRIP13's mechanism of action on the REV7-Shieldin complex.

Main Results:

• TRIP13 acts as a novel regulator by disabling the pro-C-NHEJ cascade.
• TRIP13 promotes a conformational change in the HORMA protein REV7, thereby inhibiting the REV7-Shieldin complex.
• This inhibition facilitates DNA end-resection, favoring HR over C-NHEJ.

Conclusions:

• TRIP13 plays a critical role in promoting HR by antagonizing the 53BP1-REV7-Shieldin pathway.
• Understanding TRIP13's function offers new insights into therapeutic strategies for BRCA1-deficient cancers and PARP inhibitor resistance.
• Further research is warranted to experimentally validate the proposed mechanisms and clinical implications.